| Literature DB >> 35834023 |
Katherine A Collins1, Leanna M Ross2, Cris A Slentz1, Kim M Huffman1, William E Kraus1.
Abstract
As type 2 diabetes remains a leading cause of morbidity and mortality, identifying the most appropriate preventive treatment early in the development of disease is an important public health matter. In general, lifestyle interventions incorporating exercise and weight loss via caloric restriction improve cardiometabolic risk by impacting several key markers of insulin sensitivity and glucose homeostasis. However, variations in the effects of specific types of exercise interventions on these markers have led to conflicting results surrounding the optimal amount, intensity, and mode of exercise for optimal effects. Moreover, the addition of weight loss via caloric restriction to exercise interventions appears to differentially impact changes in body composition, metabolism, and insulin sensitivity compared to exercise alone. Determining the optimal amount, intensity, and mode of exercise having the most beneficial impact on glycemic status is both: (1) clinically important to provide guidelines for appropriate exercise prescription; and (2) physiologically important to understand the pathways by which exercise-with and without weight loss-impacts glycemic status to enhance precision lifestyle medicine. Thus, the purposes of this narrative review are to: (1) summarize findings from the three Studies of a Targeted Risk Reduction Intervention through Defined Exercise (STRRIDE) randomized trials regarding the differential effects of exercise amount, intensity, and mode on insulin action and glucose homeostasis markers; and (2) compare the STRRIDE findings to other published dose-response exercise trials in order to piece together the various physiologic pathways by which specific exercise interventions-with or without weight loss-impact glycemic status.Entities:
Keywords: Aerobic exercise; Calorie restriction; Cardiometabolic health; Glycemic control; Intervention; Lifestyle medicine; Prediabetes; Resistance exercise; Type 2 diabetes mellitus; Weight loss
Year: 2022 PMID: 35834023 PMCID: PMC9283590 DOI: 10.1186/s40798-022-00480-5
Source DB: PubMed Journal: Sports Med Open ISSN: 2198-9761
Exercise intervention groups in the STRRIDE trials
| Study and intervention group | Exercise prescription | ||
|---|---|---|---|
| High Amount/Vigorous Intensity | 64 | 23 KKW | 65–80% peak V̇O2 |
| Low Amount/Vigorous Intensity | 58 | 14 KKW | 65–80% peak V̇O2 |
| Low Amount/Moderate Intensity | 57 | 14 KKW | 40–55% peak V̇O2 |
| Aerobic Training (Low Amount/Vigorous Intensity) | 47 | 14 KKW | 65–80% peak V̇O2 |
| Resistance Training | 51 | 3 days/week, 3 sets/day, 8–12 reps of 8 exercises | |
| Aerobic + Resistance Training | 44 | 14 KKW at 65–80% peak V̇O2 + 3 days/week, 3 sets/day, 8–12 reps of 8 exercises | |
| High Amount/Vigorous Intensity | 38 | 16 KKW | 65–80% V̇O2 reserve |
| High Amount/Moderate Intensity | 40 | 16 KKW | 40–55% V̇O2 reserve |
| Low Amount/Moderate Intensity | 35 | 10 KKW | 40–55% V̇O2 reserve |
| Clinical Lifestyle Intervention | 37 | 10 KKW at 40–55% V̇O2 reserve + caloric restriction to reduce body weight by 7% | |
KKW, kcal exercise energy expenditure/kilogram of body weight/week; 23 KKW, calorically equivalent of walking/jogging approximately 20 miles/week for a 90 kg person; 14 KKW, calorically equivalent of walking/jogging approximately 12 miles/week for a 90 kg person; 16 KKW, calorically equivalent of walking/jogging approximately 13.8 miles/week for a 90 kg person; 10 KKW, calorically equivalent of walking/jogging approximately 8.6 miles/week for a 90 kg person
Baseline and change scores for fasting and IVGTT parameters in STRRIDE I by group
| Control | Low amount/moderate intensity | Low amount/vigorous intensity | High amount/vigorous intensity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change |
| Baseline | Change |
| Baseline | Change |
| Baseline | Change |
| |
|
| ||||||||||||
| Glucose (mmol/L) | 5.0 (0.6) | 0.2 (0.5) | ** | 5.1 (0.5) | − 0.01 (0.5) | NS | 5.1 (0.5) | 0.1 (0.5) | NS | 5.2 (0.6) | 0.03 (0.5) | NS |
| Insulin (pmol/L) | 51.0 (28.2) | 5.4 (19.8) | * | 61.8 (48.6) | − 15.0 (33.6) | ** | 52.8 (24.6) | − 9.0 (24.6) | ** | 57.6 (19.8) | − 7.8 (19.8) | ** |
| HOMA-IR | 1.1 (0.6) | 0.1 (0.4) | * | 1.3 (1.0) | − 0.3 (0.7) | ** | 1.2 (0.7) | − 0.2 (0.5) | ** | 1.2 (0.7) | − 0.2 (0.4) | ** |
| LP-IRa | 53.1 (25.2) | − 0.3 (17.4) | NS | 60.0 (25.0) | − 9.3 (15.5) | *** | 52.1 (25.4) | − 5.2 (15.9) | * | 54.7 (24.3) | − 6.1 (13.8) | ** |
| DRIa | 39.9 (21.3) | − 0.2 (12.0) | NS | 43.7 (18.3) | − 4.7 (14.4) | * | 43.0 (20.0) | − 2.6 (8.9) | NS | 44.2 (20.4) | − 1.5 (12.2) | NS |
|
| ||||||||||||
| DI | 1562 (1444) | − 65 (893) | NS | 1270 (1147) | 742 (1680) | ** | 1533 (1362) | 255 (1023) | NS | 1305 (1121) | 255 (685) | ** |
| AIRg (mU/L/min) | 490.6 (431.2) | 22.1 (232.6) | NS | 457.3 (334.1) | − 9.8 (207.3) | NS | 445.5 (352.7) | − 42.8 (216.4) | NS | 505.6 (426.6) | − 76.6 (217.6) | ** |
| Si (mU/L/min) | 3.5 (2.1) | − 0.4 (1.7) | NS | 3.1 (2.2) | 1.7 (2.5) | *** | 3.7 (2.1) | 0.8 (1.8) | ** | 3.2 (2.5) | 1.2 (2.1) | *** |
Data presented as means (SD)
AIRg, acute insulin response to intravenous glucose; DI, disposition index; DRI, Diabetes Risk Index; HOMA, homeostatic model assessment [(fasting glucose × fasting insulin)/22.5]; IVGTT, intravenous glucose tolerance test; LP-IR, Lipoprotein Insulin Resistance Index; NS, not significant; Si, insulin sensitivity index
*p < 0.05; **p < 0.01; ***p < 0.001
aLP-IR and DRI sample sizes are: Con (n = 53); Low/Mod (n = 44); Low/Vig (n = 48); High/Vig (n = 49)
Baseline and change scores for fasting and OGTT parameters in STRRIDE-PD by group
| Low amount/moderate intensity ( | High amount/moderate intensity ( | High amount/vigorous intensity ( | Clinical lifestyle | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change |
| Baseline | Change |
| Baseline | Change |
| Baseline | Change |
| |
|
| ||||||||||||
| Glucose (mmol/L) | 5.87 (0.6) | 0.05 (0.3) | NS | 5.91 (0.5) | − 0.07 (0.4) | NS | 5.79 (0.5) | 0.06 (0.4) | NS | 5.86 (0.6) | − 0.32 (0.4) | *** |
| Insulin (pmol/L) | 48.4 (24) | − 5.4 (16) | NS | 45.3 (31) | − 6.4 (24) | NS | 49.8 (44) | − 9.3 (24) | * | 50.0 (28) | − 21.5 (22) | *** |
| HOMA-IR | 1.9 (1.0) | − 0.2 (0.7) | NS | 1.8 (1.3) | − 0.3 (1.0) | NS | 2.0 (1.9) | − 0.4 (1.0) | * | 2.0 (1.2) | − 0.9 (0.9) | *** |
| LP-IRa | 54.5 (22.4) | − 0.6 (13.9) | NS | 55.2 (22.6) | − 4.4 (16.2) | NS | 55.2 (22.4) | − 4.4 (8.2) | ** | 57.1 (18.3) | − 12.4 (14.1) | *** |
| DRIa | 37.9 (16.8) | − 0.6 (10.0) | NS | 38.5 (18.3) | − 1.4 (11.5) | NS | 39.1 (17.1) | − 2.8 (8.2) | * | 39.2 (16.8) | − 8.3 (10.4) | *** |
|
| ||||||||||||
| Glucose AUC (mmol/L × 120 min) | 1039 (219) | − 49 (143) | NS | 1042 (192) | − 73 (123) | *** | 1031 (211) | − 22 (103) | NS | 1050 (232) | − 96 (132) | *** |
| Insulin AUC (pmol/L × 120 min) | 955 (645) | − 166 (330) | ** | 990 (666) | − 264 (452) | *** | 1135 (999) | − 246 (452) | ** | 982 (527) | − 348 (350) | *** |
| Matsuda Index | 5.14 (3.2) | 1.08 (1.7) | *** | 5.55 (3.5) | 1.35 (2.7) | ** | 5.25 (3.0) | 1.38 (2.4) | *** | 4.99 (3.3) | 3.98 (3.9) | *** |
Data presented as means (SD)
AUC, area under the curve; DRI, Diabetes Risk Index; HOMA, homeostatic model assessment [(fasting glucose x fasting insulin)/22.5]; NS, not significant; OGTT, oral glucose tolerance test; LP-IR, Lipoprotein Insulin Resistance Index
*p < 0.05; **p < 0.01; ***p < 0.001
aLP-IR and DRI sample sizes are: Low/Mod (n = 42); High/Mod (n = 45); High/Vig (n = 40); CL (n = 43)
Fig. 1Disposition Index (DI = Si × AIRg) percentiles for STRRIDE I (panel a) and STRRIDE AT/RT (panel b). Type 2 diabetes risk is significantly modified only by changes across the isobar (DI) lines, with a greater percentile being representative of greater insulin sensitivity and lesser diabetes risk. Pre-intervention data points are represented by open symbols. Post-intervention data points are represented by closed symbols. Arrows represent the direction of change in DI following exercise training by intervention group. In panel a, diamonds = inactive control group; circles = low-amount/moderate-intensity group; triangles = low-amount/vigorous-intensity group; and squares = high-amount/vigorous-intensity group. In panel b, circles = aerobic training group; squares = resistance training group; and triangles = aerobic plus resistance training group. DI = disposition index; Si = insulin sensitivity index; AIRg = acute insulin response to glucose
Summary of studies evaluating aerobic exercise amount and intensity effects on markers of insulin sensitivity and glucose homeostasis
| Study | Population | Training type/intervention length | Groups | Measure | Results | |
|---|---|---|---|---|---|---|
| DiPietro et al. [ | 25 | BMI < 30 kg/m2 Women | 9-month aerobic intervention | Hyperinsulinemic–euglycemic clamp | No change in exercise groups | |
No change in exercise groups | ||||||
Significant increase in Vig. Group | ||||||
Significant decrease in Mod. Group | ||||||
| Coker et al. [ | 21 | BMI: ≥ 26 to < 37 kg/m2 65 to 90 yrs | 12-week aerobic intervention | Significant increase in Vig. Group | ||
Significant increase in Vig. Group | ||||||
| Ross et al. [ | 300 | Abdominal obesity: Men WC > 102 cm or Women WC > 88 cm 35 to 65 yrs | 24-week aerobic intervention | Oral glucose tolerance test | Significant difference in change between High/Vig vs. Control Significant difference in change between High/Vig vs. Low/Mod | |
Significant difference in change between High/Vig vs. Low/Mod | ||||||
Significant difference in change between High/Vig and High/Mod vs. Control | ||||||
Significant difference in change between High/Vig and High/Mod vs. Control Significant difference in change between High/Vig vs. Low/Mod | ||||||
| Malin et al. [ | 31 | Average BMI: 32.1 kg/m2 Average age 61.4 yrs Prediabetes Nonsmoking Physically inactive | 13-day aerobic intervention | Oral glucose tolerance test | Significant decrease in both groups | |
Significant decrease in both groups | ||||||
Significant increase in both groups (early and total-phase) | ||||||
Significant increase in both groups |
AUC, area under the curve; BMI, body mass index; HR, heart rate; WC, waist circumference
Baseline and change scores for fasting and IVGTT parameters in STRRIDE AT/RT by group
| Aerobic training | Resistance training | Aerobic + resistance training | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change |
| Baseline | Change |
| Baseline | Change |
| |
|
| 42 | 43 | 40 | ||||||
|
| |||||||||
| Glucose (mmol/L) | 5.3 (0.7) | − 0.1 (0.6) | NS | 5.5 (0.6) | − 0.03 (0.5) | NS | 5.1 (0.5) | 0.01 (0.5) | NS |
| Insulin (pmol/L) | 56.4 (33.6) | − 10.2 (18.0) | *** | 51.6 (22.8) | − 2.4 (28.2) | NS | 52.8 (27.0) | − 9.6 (26.4) | * |
| HOMA-IR | 2.3 (1.5) | − 0.5 (0.9) | ** | 2.1 (1.1) | − 0.1 (1.3) | NS | 2.0 (1.1) | − 0.4 (1.1) | * |
| LP-IRa | 54.0 (25.5) | − 4.8 (17.2) | NS | 48.7 (24.4) | − 1.7 (14.0) | NS | 54.3 (20.4) | − 10.1 (16.8) | *** |
| DRIa | 45.9 (19.2) | − 2.9 (11.9) | NS | 40.8 (18.2) | − 0.8 (12.2) | NS | 46.0 (16.3) | − 6.2 (11.0) | *** |
Data presented as means (SD)
AIRg, acute insulin response to intravenous glucose; DI, disposition index; DRI, Diabetes Risk Index; HOMA, homeostatic model assessment [(fasting glucose x fasting insulin)/22.5]; IVGTT, intravenous glucose tolerance test; LP-IR, Lipoprotein Insulin Resistance Index; NS, not significant; Si, insulin sensitivity index
*p < 0.05; **p < 0.01; ***p < 0.001
aLP-IR and DRI sample sizes are: aerobic training (n = 46); resistance training (n = 50); aerobic + resistance training (n = 43)
Summary of studies evaluating exercise mode effects on markers of insulin sensitivity and glucose homeostasis
| Study | Population | Training type/intervention length | Groups | Measure | Results | |
|---|---|---|---|---|---|---|
| Sigal et al. (DARE Trial) [ | 251 | 39 to 70 yrs Type 2 diabetes Physically inactive | 22-week aerobic and resistance intervention | Turbidimetric immunioinhibition | Significant difference in change between aerobic and resistance training groups vs. control group Significant difference in change between aerobic and resistance training groups vs. aerobic + resistance training group | |
| Church et al. (HART-D Trial), [ | 262 | 30 to 75 yrs BMI < 48 kg/m2 Type 2 diabetes Sedentary | 9-month aerobic and resistance intervention | Automated glycosylated hemoglobin analyzer | Significant decrease in Aerobic + Resistance training group Significant difference in change between aerobic and aerobic + resistance groups vs. control group when analysis population was limited to participants with a baseline hemoglobin A1c ≥ 7.0% |
AUC, area under the curve; HR, heart rate; KKW, kcal energy expenditure/kg of body weight/week
Summary of studies evaluating lifestyle intervention effects on markers of insulin sensitivity and glucose homeostasis
| Study | Population | Training type/intervention length | Groups | Measure | Results | |
|---|---|---|---|---|---|---|
| Cox et al. [ | 60 | Average BMI 31.0 kg/m2 20 to 50 yrs Men Nonsmoking Sedentary No substantial weight loss in previous 12 months | 16-week caloric restriction and aerobic exercise intervention | Oral glucose tolerance test | Vig. intensity groups had greater decrease compared to light-intensity groups | |
Significant decrease in Energy Restricted Diet + Vig. Intensity group | ||||||
Significant decrease in Energy Restricted Diet + Vig. Intensity group Vig. intensity groups had greater decrease compared to light-intensity group | ||||||
Significant decrease in both Energy Restricted Diet groups Vig. intensity groups had greater decrease compared to light-intensity group Energy restriction groups had greater decrease compared to maintain diet groups | ||||||
| Larson-Meyer et al. [ | 48 | 25 ≤ BMI ≤ 30 kg/m2 Men (25–50 years) and women (25–45 years) Nonsmoking Exercise ≤ twice per week | 6-month caloric restriction and aerobic exercise intervention | Intravenous glucose tolerance test | No change | |
Significant decrease in all calorie deficit groups | ||||||
Significant decrease in Calorie Restriction plus Exercise and Very Low-Calorie Diet groups | ||||||
Significant decrease in all calorie deficit groups | ||||||
| Bouchonville et al. [ | 107 | BMI > 30 kg/m2 > 65 yrs Weight stable previous 12 months Physically inactive with mild-to-moderate physical frailty | 12-month caloric restriction and aerobic exercise intervention | Oral glucose tolerance test | Significant increase in Diet group and Diet + Exercise group Significant difference in change between Diet, Exercise, and Control groups vs. Diet + Exercise group | |
Significant decrease in Diet group and Diet + Exercise group Significant difference in change between Diet vs. Control and Exercise vs. Diet + Exercise | ||||||
Significant decrease in Diet and Diet + Exercise groups Significant difference in change between Diet vs. Control and Exercise vs. Diet + Exercise | ||||||
Significant decrease in Diet and Diet + Exercise groups Significant difference in change between Exercise vs. Diet + Exercise | ||||||
| Gilbertson et al. [ | 29 | Average BMI: 35.9 kg/m2 18 to 71 yrs Prediabetes Sedentary | 16-week caloric restriction and aerobic exercise intervention | Blood draw | Significant decrease in both groups over time | |
Significant decrease in both groups over time | ||||||
No significant changes | ||||||
No significant changes | ||||||
| Brennan et al. [ | 84 | BMI ≥ 30 kg/m2 60 to 80 yrs Weight stable previous 6 months Physically inactive Nonsmoking Systolic BP < 150 mmHg and Diastolic BP < 95 mmHg | 6-month caloric restriction and exercise intervention | Hyperinsulinemic–euglycemic clamp | No between-group differences in change | |
Diet + Exercise group had significantly greater improvement than control group | ||||||
Diet + Exercise group had significantly greater improvement than control group | ||||||
Diet + Exercise group improved significantly compared to control After controlling for % weight loss, no significant between-group differences | ||||||
No between-group differences in change |
AUC, area under the curve; BP, blood pressure; BMI, body mass index; HR, heart rate; HOMA-IR, homeostatic model assessment of insulin resistance; 1 RM, 1 repetition maximum